AR101815A1 - Compuestos y composiciones como inhibidores de quinasa - Google Patents
Compuestos y composiciones como inhibidores de quinasaInfo
- Publication number
- AR101815A1 AR101815A1 ARP150102898A ARP150102898A AR101815A1 AR 101815 A1 AR101815 A1 AR 101815A1 AR P150102898 A ARP150102898 A AR P150102898A AR P150102898 A ARP150102898 A AR P150102898A AR 101815 A1 AR101815 A1 AR 101815A1
- Authority
- AR
- Argentina
- Prior art keywords
- compositions
- compounds
- och2chr3r4
- quinasa
- inhibitors
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 125000006002 1,1-difluoroethyl group Chemical group 0.000 abstract 1
- ZMLHBBXPXZXTSP-UHFFFAOYSA-N 2-fluoropropane Chemical group C[C](C)F ZMLHBBXPXZXTSP-UHFFFAOYSA-N 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462049469P | 2014-09-12 | 2014-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR101815A1 true AR101815A1 (es) | 2017-01-11 |
Family
ID=54148595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150102898A AR101815A1 (es) | 2014-09-12 | 2015-09-11 | Compuestos y composiciones como inhibidores de quinasa |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US9573969B2 (enExample) |
| EP (1) | EP3191472B1 (enExample) |
| JP (1) | JP6678655B2 (enExample) |
| KR (1) | KR20170053686A (enExample) |
| CN (1) | CN107108671B (enExample) |
| AP (1) | AP2017009830A0 (enExample) |
| AR (1) | AR101815A1 (enExample) |
| AU (1) | AU2015313782B2 (enExample) |
| BR (1) | BR112017004741A2 (enExample) |
| CA (1) | CA2960971A1 (enExample) |
| CL (1) | CL2017000541A1 (enExample) |
| CO (1) | CO2017002292A2 (enExample) |
| CR (1) | CR20170092A (enExample) |
| CU (1) | CU20170026A7 (enExample) |
| DO (1) | DOP2017000066A (enExample) |
| EA (1) | EA031061B1 (enExample) |
| EC (1) | ECSP17021897A (enExample) |
| ES (1) | ES2729243T3 (enExample) |
| IL (1) | IL250950A0 (enExample) |
| MX (1) | MX2017003233A (enExample) |
| NI (1) | NI201700029A (enExample) |
| PE (1) | PE20171338A1 (enExample) |
| PH (1) | PH12017500416A1 (enExample) |
| SG (1) | SG11201701734QA (enExample) |
| SV (1) | SV2017005405A (enExample) |
| TN (1) | TN2017000075A1 (enExample) |
| TW (1) | TWI603977B (enExample) |
| UY (1) | UY36294A (enExample) |
| WO (1) | WO2016038581A1 (enExample) |
| ZA (1) | ZA201701633B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| GEP201706780B (en) | 2013-03-14 | 2017-11-27 | Boehringer Ingelheim Int | Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c |
| TN2016000270A1 (en) * | 2014-01-14 | 2017-10-06 | Millennium Pharm Inc | Heteroaryls and uses thereof. |
| UA118610C2 (uk) | 2014-09-12 | 2019-02-11 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Спіроциклічні інгібітори катепсину c |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| WO2018051306A1 (en) | 2016-09-19 | 2018-03-22 | Novartis Ag | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor |
| KR20240032157A (ko) | 2017-05-02 | 2024-03-08 | 노파르티스 아게 | 병용 요법 |
| WO2019026007A1 (en) * | 2017-08-03 | 2019-02-07 | Novartis Ag | THERAPEUTIC ASSOCIATION OF THIRD GENERATION TYFRSINE KINASE INHIBITOR AND RAF INHIBITOR |
| US20230081390A1 (en) * | 2019-03-22 | 2023-03-16 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| EP3962484A4 (en) | 2019-05-03 | 2023-01-18 | Kinnate Biopharma Inc. | RAF KINASE INHIBITORS |
| MX2021013817A (es) * | 2019-05-13 | 2021-12-14 | Novartis Ag | Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer. |
| EP4048259A4 (en) | 2019-10-24 | 2023-08-02 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| WO2021110141A1 (zh) * | 2019-12-06 | 2021-06-10 | 南京明德新药研发有限公司 | Pan-RAF激酶抑制剂的联芳基化合物 |
| WO2022060996A1 (en) | 2020-09-18 | 2022-03-24 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| WO2022066580A1 (en) * | 2020-09-23 | 2022-03-31 | Kinnate Biopharma Inc. | Raf degrading compounds |
| US11377431B2 (en) | 2020-10-12 | 2022-07-05 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
| BR112023021913A2 (pt) * | 2021-04-23 | 2024-01-16 | Kinnate Biopharma Inc | Tratamento de câncer com inibidor de raf |
| MX2023012521A (es) * | 2021-04-23 | 2023-12-15 | Kinnate Biopharma Inc | Formas en estado solido de (s)-n-(3-(2-((r)-1-hidroxipropano-2-il) amino)-6-morfolinopiridin-4-il)-4-metilfenil)-3-(2,2,2-trifluoroe til)pirrolidin-1-carboxamida y sales de las mismas. |
| CN117337292A (zh) * | 2021-05-12 | 2024-01-02 | 勃林格殷格翰国际有限公司 | 作为cGAS抑制剂的具有N-连接环状取代基的吡啶衍生物 |
Family Cites Families (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3707475A (en) | 1970-11-16 | 1972-12-26 | Pfizer | Antiinflammatory imidazoles |
| DE3029376A1 (de) | 1980-07-31 | 1982-03-18 | Nepera Chemical Co. Inc., Harriman, N.Y. | Verfahren zur herstellung von 2,4,5-tris-pyridylimidazolen |
| EP0149884B1 (en) | 1983-09-09 | 1992-12-16 | Takeda Chemical Industries, Ltd. | 5-pyridyl-1,3-thiazole derivatives, their production and use |
| JP2722586B2 (ja) | 1989-01-13 | 1998-03-04 | 大正製薬株式会社 | インドリルイミダゾール誘導体 |
| JP2808460B2 (ja) | 1989-11-16 | 1998-10-08 | 大正製薬株式会社 | イミダゾール誘導体 |
| US6358932B1 (en) | 1994-05-31 | 2002-03-19 | Isis Pharmaceticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
| US5717100A (en) | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
| GB2306108A (en) | 1995-10-13 | 1997-04-30 | Merck & Co Inc | Treatment of Raf-mediated cancers with imidazole derivatives |
| WO1998008845A1 (en) | 1996-08-27 | 1998-03-05 | Novartis Ag | Herbicidal s-substituted 1,2,4,6-thiatriazines |
| JP4713698B2 (ja) | 1997-03-05 | 2011-06-29 | スージェン， インク． | 疎水性薬剤の処方 |
| AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
| GB9711650D0 (en) | 1997-06-05 | 1997-07-30 | Pfizer Ltd | Compounds useful in therapy |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| US6211177B1 (en) | 1998-11-24 | 2001-04-03 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives |
| EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
| DE60001229T2 (de) | 1999-04-09 | 2003-10-30 | Smithkline Beecham Corp., Philadelphia | Triarylimidazole |
| PT1169038E (pt) | 1999-04-15 | 2012-10-26 | Bristol Myers Squibb Co | Inibidores cíclicos da proteína tirosina cinase |
| JP2000302680A (ja) | 1999-04-23 | 2000-10-31 | Takeda Chem Ind Ltd | 脳保護剤 |
| US6310574B1 (en) | 1999-08-05 | 2001-10-30 | Vega Grieshaber Kg | Level transmitter |
| ES2270867T3 (es) | 1999-09-23 | 2007-04-16 | Astrazeneca Ab | Compuestos de quinazolina terapeuticos. |
| HK1050190A1 (zh) | 1999-11-22 | 2003-06-13 | Smithkline Beecham Plc | 咪唑衍生物和它们做为raf激酶抑制剂的用途 |
| NZ520628A (en) | 2000-01-18 | 2004-05-28 | Vertex Pharma | thiazole, oxazole, imdazole or pyrazole substituted pyrazole derivatives useful as treating bacterial infections |
| WO2001052846A1 (en) | 2000-01-18 | 2001-07-26 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
| CO5271680A1 (es) | 2000-02-21 | 2003-04-30 | Smithkline Beecham Corp | Compuestos |
| JP2003525936A (ja) | 2000-03-06 | 2003-09-02 | スミスクライン ビーチャム パブリック リミテッド カンパニー | Ｒａｆキナーゼ阻害物質としてのイミダゾール誘導体 |
| GB0005357D0 (en) | 2000-03-06 | 2000-04-26 | Smithkline Beecham Plc | Compounds |
| GB0007405D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
| EP1268474A2 (en) | 2000-03-30 | 2003-01-02 | Takeda Chemical Industries, Ltd. | Substituted 1,3-thiazole compounds, their production and use |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| MXPA02012314A (es) | 2000-06-12 | 2004-09-06 | Eisai Co Ltd | Compuestos de 1,2-dihidropiridina, metodo de fabricacion y utilizacion de los mismos. |
| HUP0400651A2 (hu) | 2000-11-07 | 2004-06-28 | Bristol-Myers Squibb Company | Szerin proteáz inhibitorokként alkalmazható savszármazékok és ezeket tartalmazó gyógyszerkészítmények |
| US20040053943A1 (en) | 2000-11-20 | 2004-03-18 | Adams Jerry L. | Novel compounds |
| EP1341771A2 (en) | 2000-11-29 | 2003-09-10 | Glaxo Group Limited | Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors |
| WO2002064136A2 (en) | 2001-01-26 | 2002-08-22 | Chugai Seiyaku Kabushiki Kaisha | Malonyl-coa decarboxylase inhibitors useful as metabolic modulators |
| WO2002062792A1 (en) | 2001-02-02 | 2002-08-15 | Takeda Chemical Industries, Ltd. | Jnk inhibitor |
| WO2002076960A1 (en) | 2001-03-22 | 2002-10-03 | Abbott Gmbh & Co. Kg | Transition metal mediated process |
| JP2002338537A (ja) | 2001-05-16 | 2002-11-27 | Mitsubishi Pharma Corp | アミド化合物およびその医薬用途 |
| GB0112348D0 (en) | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
| GB0129260D0 (en) | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
| US7071216B2 (en) | 2002-03-29 | 2006-07-04 | Chiron Corporation | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase |
| US8299108B2 (en) | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
| AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| HRP20050252A2 (en) | 2002-09-18 | 2005-10-31 | Pfizer Products Inc. | Novel imidazole compounds as transforming growth factor (tfg) inhibitors |
| WO2004026863A1 (en) | 2002-09-18 | 2004-04-01 | Pfizer Products Inc. | Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors |
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| US7531553B2 (en) | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
| US7449582B2 (en) | 2003-10-08 | 2008-11-11 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| DE602004021838D1 (de) | 2003-10-16 | 2009-08-13 | Novartis Vaccines & Diagnostic | Substituierte benzazole und ihre verwendung als raf-kinase-hemmer |
| US8969372B2 (en) | 2003-11-14 | 2015-03-03 | Aptose Boisciences Inc. | Aryl imidazoles and their use as anti-cancer agents |
| KR101150077B1 (ko) | 2004-03-05 | 2012-06-01 | 다이쇼 세이야꾸 가부시끼가이샤 | 티아졸 유도체 |
| KR100749566B1 (ko) | 2004-04-21 | 2007-08-16 | 이화여자대학교 산학협력단 | Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체 |
| WO2005105814A1 (en) | 2004-04-28 | 2005-11-10 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
| PE20060315A1 (es) | 2004-05-24 | 2006-05-15 | Irm Llc | Compuestos de tiazol como moduladores de ppar |
| US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| GB0415365D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
| GB0415367D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
| GB0415364D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
| JP2008511631A (ja) | 2004-08-31 | 2008-04-17 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | ＴＧＦ−βインヒビターとしてのピリミジニルイミダゾール |
| WO2006038734A1 (en) | 2004-10-08 | 2006-04-13 | Astellas Pharma Inc. | Pyridazinone derivatives cytokines inhibitors |
| AU2005295734A1 (en) | 2004-10-15 | 2006-04-27 | Biogen Idec Ma Inc. | Methods of treating vascular injuries |
| JP2007246520A (ja) | 2006-02-15 | 2007-09-27 | Takeda Yuichiro | Ｒａｇｅ阻害剤 |
| EP2007393B1 (en) | 2006-04-07 | 2013-08-21 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers |
| WO2008071605A2 (en) | 2006-12-15 | 2008-06-19 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
| JP5140154B2 (ja) | 2007-06-27 | 2013-02-06 | アストラゼネカ・アクチエボラーグ | ピラジノン誘導体および肺疾患の処置におけるそれらの使用 |
| AU2008273017C1 (en) | 2007-06-29 | 2014-02-13 | Millennium Pharmaceuticals, Inc. | Heterocyclic compounds useful as Raf kinase inhibitors |
| TWI444379B (zh) | 2007-06-29 | 2014-07-11 | Sunesis Pharmaceuticals Inc | 有用於作為Ｒａｆ激酶抑制劑之化合物 |
| JP2010531850A (ja) | 2007-07-02 | 2010-09-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規化合物 |
| CN101796048A (zh) | 2007-07-09 | 2010-08-04 | 阿斯利康(瑞典)有限公司 | 用于治疗增殖病症的三取代的嘧啶衍生物 |
| MX2010000617A (es) | 2007-07-17 | 2010-05-17 | Plexxikon Inc | Compuestos y metodos para modulacion de cinasa, e indicaciones de estos. |
| US8293747B2 (en) | 2007-07-19 | 2012-10-23 | Merck Sharp & Dohme Corp. | Heterocyclic amide compounds as protein kinase inhibitors |
| US20110190280A1 (en) | 2007-08-29 | 2011-08-04 | George Adjabeng | Thiazole And Oxazole Kinase Inhibitors |
| TW200916458A (en) | 2007-09-05 | 2009-04-16 | Astrazeneca Ab | Heterocyclic compounds and methods of use thereof |
| WO2009047163A1 (en) | 2007-10-10 | 2009-04-16 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
| TW200940537A (en) | 2008-02-26 | 2009-10-01 | Astrazeneca Ab | Heterocyclic urea derivatives and methods of use thereof |
| EA201001456A1 (ru) | 2008-03-21 | 2011-06-30 | Новартис Аг | Новые гетероциклические соединения и их применение |
| US8865732B2 (en) | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| EA201001847A1 (ru) | 2008-06-11 | 2011-08-30 | Айрм Ллк | Соединения и композиции, применяемые для лечения малярии |
| AU2009273197B2 (en) | 2008-07-24 | 2014-01-16 | Nerviano Medical Sciences S.R.L. | 3,4-diarylpyrazoles as protein kinase inhibitors |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| ES2921576T3 (es) | 2008-12-19 | 2022-08-29 | Vertex Pharma | Compuestos útiles como inhibidores de la quinasa ATR |
| JP2012514044A (ja) * | 2008-12-30 | 2012-06-21 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | Ｒａｆキナーゼ阻害剤として有用なヘテロアリール化合物 |
| SG178561A1 (en) * | 2009-08-28 | 2012-03-29 | Array Biopharma Inc | 1h-pyrazolo [ 3, 4-b] pyridine compounds for inhibiting raf kinase |
| US8242260B2 (en) | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
| CN102471310A (zh) | 2009-09-04 | 2012-05-23 | 诺瓦提斯公司 | 用于治疗增生性疾病的联吡啶化合物 |
| EP2498608A4 (en) | 2009-11-10 | 2013-04-24 | Glaxosmithkline Llc | BENZOLSULFONAMIDE THIAZOL AND OXAZOLE COMPOUNDS |
| US9315491B2 (en) | 2009-12-28 | 2016-04-19 | Development Center For Biotechnology | Pyrimidine compounds as mTOR and PI3K inhibitors |
| PL2520575T3 (pl) | 2009-12-28 | 2017-05-31 | General Incorporated Association Pharma Valley Project Supporting Organization | Związek 1,3,4-oksadiazolo-2-karboksyamidowy |
| KR20110123657A (ko) | 2010-05-07 | 2011-11-15 | 에스케이케미칼주식회사 | 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물 |
| US20130096149A1 (en) | 2010-06-25 | 2013-04-18 | Novartis Ag | Heteroaryl compounds and compositions as protein kinase inhibitors |
| CN101993415B (zh) | 2010-09-15 | 2013-08-14 | 北京韩美药品有限公司 | 作为Hedgehog通路抑制剂的化合物以及包含该化合物的药物组合物及其应用 |
| PL2672967T3 (pl) | 2011-02-07 | 2019-04-30 | Plexxikon Inc | Związki i sposoby modulacji kinaz i wskazania ku temu |
| WO2013022766A1 (en) | 2011-08-05 | 2013-02-14 | Flynn Gary A | Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors |
| JP6134319B2 (ja) | 2011-09-01 | 2017-05-24 | ノバルティス アーゲー | ｃ−ｋｉｔキナーゼインヒビターとしての化合物及び組成物 |
| CN102993199A (zh) * | 2011-09-09 | 2013-03-27 | 山东轩竹医药科技有限公司 | 杂环取代的吡啶并吡咯激酶抑制剂 |
| EP2758379B1 (en) | 2011-09-21 | 2016-10-19 | Cellzome Limited | Urea and carbamate derivatives of 2-morpholino-1,3,5-triazine as mTOR inhibitors for the treatment of immunological or proliferative diseases |
| WO2013164769A1 (en) | 2012-05-02 | 2013-11-07 | Lupin Limited | Substituted pyridine compounds as crac modulators |
| EA201492005A1 (ru) | 2012-05-15 | 2015-04-30 | Новартис Аг | Бензамидные производные для ингибирования активности abl1, abl2 и bcr-abl1 |
| WO2014008214A1 (en) | 2012-07-02 | 2014-01-09 | Biogen Idec Ma Inc. | Biaryl-containing compounds as inverse agonists of ror-gamma receptors |
| EP2903613B1 (en) | 2012-10-08 | 2017-11-22 | Merck Sharp & Dohme Corp. | Pyrazole derivatives useful as inhibitors of irak4 activity |
| US9242969B2 (en) * | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| UY36294A (es) * | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
-
2015
- 2015-09-10 UY UY0001036294A patent/UY36294A/es not_active Application Discontinuation
- 2015-09-11 SG SG11201701734QA patent/SG11201701734QA/en unknown
- 2015-09-11 WO PCT/IB2015/056986 patent/WO2016038581A1/en not_active Ceased
- 2015-09-11 CN CN201580061323.4A patent/CN107108671B/zh active Active
- 2015-09-11 ES ES15766660T patent/ES2729243T3/es active Active
- 2015-09-11 CA CA2960971A patent/CA2960971A1/en not_active Abandoned
- 2015-09-11 AR ARP150102898A patent/AR101815A1/es unknown
- 2015-09-11 TW TW104130161A patent/TWI603977B/zh not_active IP Right Cessation
- 2015-09-11 CR CR20170092A patent/CR20170092A/es unknown
- 2015-09-11 JP JP2017513759A patent/JP6678655B2/ja active Active
- 2015-09-11 EP EP15766660.3A patent/EP3191472B1/en active Active
- 2015-09-11 US US14/851,249 patent/US9573969B2/en active Active
- 2015-09-11 AP AP2017009830A patent/AP2017009830A0/en unknown
- 2015-09-11 CU CUP2017000026A patent/CU20170026A7/es unknown
- 2015-09-11 KR KR1020177009468A patent/KR20170053686A/ko not_active Withdrawn
- 2015-09-11 AU AU2015313782A patent/AU2015313782B2/en not_active Ceased
- 2015-09-11 TN TN2017000075A patent/TN2017000075A1/en unknown
- 2015-09-11 PE PE2017000445A patent/PE20171338A1/es not_active Application Discontinuation
- 2015-09-11 BR BR112017004741A patent/BR112017004741A2/pt not_active IP Right Cessation
- 2015-09-11 EA EA201790599A patent/EA031061B1/ru not_active IP Right Cessation
- 2015-09-11 MX MX2017003233A patent/MX2017003233A/es unknown
-
2017
- 2017-01-04 US US15/397,787 patent/US9809610B2/en active Active
- 2017-03-05 IL IL250950A patent/IL250950A0/en unknown
- 2017-03-06 PH PH12017500416A patent/PH12017500416A1/en unknown
- 2017-03-07 CL CL2017000541A patent/CL2017000541A1/es unknown
- 2017-03-07 ZA ZA2017/01633A patent/ZA201701633B/en unknown
- 2017-03-08 CO CONC2017/0002292A patent/CO2017002292A2/es unknown
- 2017-03-09 DO DO2017000066A patent/DOP2017000066A/es unknown
- 2017-03-10 NI NI201700029A patent/NI201700029A/es unknown
- 2017-03-10 SV SV2017005405A patent/SV2017005405A/es unknown
- 2017-04-07 EC ECIEPI201721897A patent/ECSP17021897A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| EA201591486A1 (ru) | Соединения имидазопиридина | |
| AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| BR112017006251A2 (pt) | novos compostos | |
| AR107428A1 (es) | COMPUESTOS DE ISOXAZOL DE ÁCIDO HIDROXÁMICO COMO INHIBIDORES DE LpxC | |
| AR091519A1 (es) | Inhibidores pirrolopirazona de tanquirasa | |
| AR094314A1 (es) | Inhibidores de fosfatidilinositol 3-cinasa | |
| PE20151781A1 (es) | Piridonamidas como moduladores de canales de sodio | |
| EA201791873A1 (ru) | Полиморф ингибиторов syk | |
| AR093759A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| AR102977A1 (es) | Inhibidores de erk | |
| AR094812A1 (es) | Derivado de piridina monocíclico como inhibidor del fgfr | |
| AR101558A1 (es) | Difluoropirrolidinas como moduladores del receptor de orexina | |
| AR091271A1 (es) | Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa | |
| EA201591634A1 (ru) | Дигидропиридопиримидиновые соединения | |
| AR095421A1 (es) | Moduladores de p2x7 | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| MX2015007883A (es) | Compuestos para protección de células. | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
| AR102217A1 (es) | Derivados de benzotiofenilo sustituidos como agonistas de gpr40 para el tratamiento de la diabetes tipo ii | |
| MA38884A1 (fr) | Composé de triazolopyridine, compositions et procédés d'utilisation associés | |
| AR095523A1 (es) | Derivados piridin-4-ilo | |
| AR105549A1 (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos | |
| AR097253A1 (es) | Derivado de pirazolilpirazol sustituido y el uso del mismo como herbicida | |
| AR091770A1 (es) | Indolcarbonitrilos moduladores selectivos de receptores androgenicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |